-
1 month ago | 
endocrinenews.endocrine.org | Jackie Oberst |Derek Bagley
A third generation of the latest cholesterol-lowering medication — PCSK9-inhibitors — will soon be available for patients with homozygous familial hypercholesterolemia (HoFH), according to a January 24 article in The Lancet Diabetes & Endocrinology.
-
1 month ago | 
endocrinenews.endocrine.org | Jackie Oberst |Derek Bagley
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized weight loss management, and researchers are now exploring how these medications can further transform obesity care and offer new possibilities for long-term weight management, according to a recent review article published in Endocrinology. Authors Lauren A. Jones and Daniel I.
-
Dec 22, 2023 | 
science.org | Tsion Abay |Jackie Oberst
For many years, the study of neurological conditions such as Parkinson’s disease, Alzheimer’s disease, and ALS, as well as the process of neurological recovery following spinal injuries or strokes, has been hindered by a lack of accurate models. Traditional research often relies on postmortem brain samples, which may not be well-preserved and typically reflect the final stages of disease. Rodent models also fall short in mimicking the complexity of human neural characteristics.
-
Dec 22, 2023 | 
science.org | Jens Bo Nielsen |Jackie Oberst
This podcast is brought to you by the Science/AAAS Custom Publishing Office. Advances in our understanding of biology—in particular how living cells function—have enabled us to recruit different types of cells for production of new medicines, new materials, new food ingredients, and even biofuels. This field is referred to as synthetic biology, a marriage of sorts between engineering and biology.
-
Nov 2, 2023 | 
science.org | Kaj Blennow |Henrik Zetterberg |Jackie Oberst
Kaj Blennow, M.D., Ph.D.Speaker Henrik Zetterberg, M.D., Ph.D.Speaker Jackie Oberst, Ph.D.Moderator Over the past 20 years, researchers have developed and helped commercialize blood tests for Alzheimer’s disease (AD). Yet only half of patients with neurodegenerative diseases end up with an AD diagnosis. For the rest, no tests are available to determine which underlying disease is responsible for failing memory or other cognitive issues. Previous attempts to develop biomarkers for other types...
-
Oct 27, 2023 | 
science.org | Inge M.W. Verberk |Jackie Oberst
Register NOWRemaining time: 7 DAYS | 22 HRS | 02 MINS Inge Verberk, Ph.D.Speaker Jackie Oberst, Ph.D.Moderator Phosphorylated tau (p-Tau), amyloid-beta (Ab) 42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are current key Alzheimer’s disease (AD) blood-based biomarkers. Interpreting results of the four biomarkers simultaneously in a clinical context is challenging due to issues such as tissue sample size, cost, and timing. A decision algorithm could aid in the...
-
Sep 8, 2023 | 
science.org | Sergiu Pasca |Jackie Oberst
Share: 12:00 Register NOWRemaining time: 3 DAYS | 08 HRS | 37 MINS Kristen Brennand, Ph.D.Speaker Sergiu P. Pasca, M.D.Speaker Jackie Oberst, Ph.D.Moderator This webinar is brought to you by the Science/AAAS Custom Publishing Office. Fearsome neurodegenerative illnesses, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and Huntington’s disease, are devastating. The exquisite complexity of the brain has made the organ difficult to study, and diseases that affect the brain...
-
Sep 8, 2023 | 
science.org | Rafael Fonseca |Jackie Oberst
Share: 12:00 Register NOWRemaining time: 8 DAYS | 22 HRS | 01 MINS Christopher S. Hourigan D.M., D.Phil., FRCPSpeaker Rafael Fonseca, M.D.Speaker Jackie Oberst, Ph.D.Moderator This webinar is brought to you by the Science/AAAS Custom Publishing Office. Measurable residual disease, or MRD (also known as minimal residual disease), refers to detectable cancer cells that remain in cancer patients after treatment. Even small numbers of these cells, particularly in blood cancers—such as leukemia,...
-
May 24, 2023 | 
science.org | Lubka T. Roumenina |Brian D. Piening |Jackie Oberst
Share: Lubka Roumenina, Ph.D.Speaker Brian Piening, Ph.D.Speaker Jackie Oberst, Ph.D.Moderator This webinar is brought to you by the Science/AAAS Custom Publishing Office. Spatial biology is an emerging field that seeks to understand the spatial organization of cells and how it affects their function. In the context of immuno-oncology, spatial biology has proven to be a critical tool for understanding the interactions between cellular and non-cellular components—cancer cells, immune system,...
-
Apr 11, 2023 | 
science.org | Panagiotis Karras |Jackie Oberst
Share: Panagiotis Karras, Ph.D.Speaker Jackie Oberst, Ph.D.Moderator This webinar is brought to you by the Science/AAAS Custom Publishing Office. Cancer is a conversation between the tumor and its surrounding host cells. Within this space, known as the tumor microenvironment, the tumor interacts with blood vessels, immune cells, fibroblasts, and the extracellular matrix. Tumors influence the tumor microenvironment by releasing extracellular signals, promoting tumor angiogenesis, and inducing...
